ResMed Inc. (RMD) Stock Price & Analysis
ResMed Inc. (RMD) closed at USD 252.83 on Thursday, October 29, 2026, up 1.06% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 250.17; the Oct 29, 2026 session ranged USD 249.6–254.27 on volume of 1,410,015 shares. Market capitalization is $35.56B, with a 52-week range of USD 180.27–277.67 (NYQ). Source: Nexqual, retrieved October 29, 2026 at 20:46 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RMD.md
Key facts (RMD)
- Analysts: Hold (mean 2.50 on a 1–5 scale) (20 analysts), mean target USD 251.52 (range 175–320).
- Next earnings: 2026-10-29, EPS estimate USD 2.67, revenue estimate $1.39B.
Analysts (RMD)
Consensus Hold (mean 2.50 on a 1–5 scale), 20 analysts; mean target USD 251.52 (low 175, high 320).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-15 | RBC Capital | Upgrade | Sector Perform → Outperform | $244 → $262 |
| 2026-08-31 | Keybanc | Target raised | Overweight | $255 → $267 |
| 2026-08-19 | Rothschild & Co | Initiated | Neutral | $230 |
| 2026-08-07 | RBC Capital | Target raised | Sector Perform | $234 → $244 |
| 2026-08-07 | Piper Sandler | Target lowered | Neutral | $233 → $225 |
| 2026-08-07 | Keybanc | Target lowered | Overweight | $260 → $255 |
| 2026-08-07 | Wells Fargo | Target lowered | Equal-Weight | $225 → $215 |
| 2026-07-15 | Mizuho | Target lowered | Outperform | $235 → $220 |
| 2026-07-13 | Citigroup | Downgrade | Buy → Neutral | $270 → $235 |
| 2026-07-10 | Jefferies | Target lowered | Hold | $240 → $225 |
| 2026-07-08 | RBC Capital | Target lowered | Outperform | $321 → $276 |
| 2026-07-08 | Wells Fargo | Target lowered | Equal-Weight | $227 → $225 |
RMD earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $2.95 | $2.89 | Beat +2.1% | — |
| — | Quarter ended Mar 31, 2026 | $2.86 | $2.80 | Beat +2.1% | — |
| — | Quarter ended Dec 31, 2025 | $2.81 | $2.72 | Beat +3.3% | — |
| — | Quarter ended Sep 30, 2025 | $2.55 | $2.50 | Beat +2.0% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
RMD recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 29, 2026 | 8-K | Quarterly results; Other material event “On October 29, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share. The dividend will have a record date of November 12, 2026, payable on December 17, 2026. The dividend will be paid in U.S. currency to holders of Resmed's common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests ("CDIs") trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record…” |
| Oct 1, 2026 | DEFA14A | Additional proxy material |
| Oct 1, 2026 | DEF 14A | Proxy statement (pay, board, votes) · period ended Jun 30, 2026 |
| Sep 1, 2026 | 8-K | Other material event “On August 31, 2026, ResMed Inc. (the "Company") entered into an accelerated share repurchase agreement (the "ASR Agreement") with Citibank, N.A. ("Citibank") to repurchase $450.0 million of the Company's shares of common stock, par value $0.004 per share ("Common Stock"). The Company is conducting the accelerated share repurchase under a repurchase authorization for an aggregate of 20,000,000 shares of Common Stock approved by its board of directors in February 2014. The Company intends to fund the accelerated…” |
| Aug 17, 2026 | 8-K | Auditor changed; Director or executive officer change, or pay arrangement; Regulation FD disclosure “(a) Dismissal of Previous Independent Registered Public Accounting Firm KPMG LLP ("KPMG") was previously the principal accountants for ResMed Inc. (the "Company" or "Resmed"). On August 13, 2026, KPMG was dismissed, effective as of that date. The reports of KPMG on the Company's consolidated financial statements for the fiscal years ended June 30, 2026 and 2025 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles.…” |
| Aug 13, 2026 | 10-K | Annual report · period ended Jun 30, 2026 |
| Aug 7, 2026 | Schedule 13G | AustralianSuper Pty Ltd: 5.7% of shares, passive 5%+ holder |
| Aug 6, 2026 | 8-K | Quarterly results; Other material event “On August 6, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share, representing an increase of 10% over the previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed's common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests ("CDIs") trading on the Australian Securities Exchange will receive an equivalent…” |
| Jul 7, 2026 | 8-K | Quarterly results; Regulation FD disclosure |
| Jul 1, 2026 | Schedule 13G/A | Reported a 1.9% stake in Nyxoah SA |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
RMD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.67 | $2.83 | -5.5% | $1.39B | 13 |
| Next quarter (ends Dec 2026) | $3.02 | $3.01 | +0.3% | $1.45B | 13 |
| Current fiscal year (ends Jun 2027) | $12.09 | $11.95 | +1.2% | $5.80B | 20 |
| Next fiscal year (ends Jun 2028) | $13.26 | $13.03 | +1.7% | $6.18B | 20 |
Key Statistics (as of October 29, 2026 at 20:46 UTC)
| Price | USD 252.83 |
|---|---|
| Change | ▲ 1.06% (up) |
| Previous Close | USD 250.17 |
| Open | USD 253.57 |
| Day Range | USD 249.6 – 254.27 |
| 52-Week Range | USD 180.27 – 277.67 |
| Volume | 1,410,015 shares |
| Market Cap | $35.56B |
| Exchange | NYQ |
Technical Analysis (RMD)
Nexqual's technical model rates RMD "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 20:46 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.38 (overbought) |
| vs SMA50 | Above (USD 231.77) |
| MACD | 7.28 (positive) |
Analyst Ratings (RMD)
Wall Street analysts rate RMD "Hold" based on 20 analysts, with a mean price target of USD 251.52 (range USD 175–320), per Nexqual as of October 29, 2026 at 20:46 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 251.52 |
| High Target | USD 320 |
| Low Target | USD 175 |
| Buy / Hold / Sell | 9 / 10 / 1 |
Earnings (RMD)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 2.67 |
| Revenue Estimate | $1.39B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.95 vs est 2.89 ▲ beat |
| 2026-03-31 | USD 2.86 vs est 2.8 ▲ beat |
| 2025-12-31 | USD 2.81 vs est 2.72 ▲ beat |
| 2025-09-30 | USD 2.55 vs est 2.5 ▲ beat |
Source: Nexqual, October 29, 2026 at 20:46 UTC.
Financials & Fundamentals (RMD)
| Total Revenue | $5.65B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.60% |
| Gross Margin | +61.62% |
| Operating Margin | +30.86% |
| Profit Margin | +26.95% |
| ROE | +24.27% |
| Debt / Equity | 0.13 |
| Current Ratio | 3.1 |
| Total Cash | $1.47B |
| Total Debt | $825.92M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $1.65B (29.2% of revenue) |
Source: Nexqual, October 29, 2026 at 20:46 UTC.
Financial Health Score (RMD)
Nexqual rates ResMed Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 20:46 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 61%, operating 33% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $1.47B cash and investments vs $659M debt (Jun 2026, SEC), net cash |
| Cash Flow | Strong — FCF $1.65B (last 4 quarters to Jun 2026, SEC), 29% margin |
| Efficiency | Strong — ROE 23%, ROA 17.0% (last 4 quarters, SEC) |
Ownership (RMD)
| Insider Ownership | +0.51% |
|---|---|
| Institutional Ownership | +73.30% |
| Shares Outstanding | 140.64M |
| Float | 143.40M |
| Short % of Float | +8.51% |
Source: Nexqual, October 29, 2026 at 20:46 UTC.
From ResMed Inc.'s Latest SEC 10-K Filing (filed 2026-08-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Another study published in Lancet Respiratory Medicine in 2019 estimated that mild to severe OSA impacts more than 936 million people worldwide, including 61 million Americans, per Lancet Respiratory Medicine in 2025.
- Our leading Residential Care Software solutions are a key enabler of our Sleep and Breathing Health business, driving revenue synergies, contributing to demand generation and providing cohesion and interoperability for our AI-driven digital platform.
- Today, our Residential Care Software solutions support residential care providers serving more than 180 million individual patient accounts.
- Our quality management system is based upon the requirements of ISO 13485, Food and Drug Administration, or FDA, Quality Management System Regulation, or QMSR, European Medical Device Regulation, or MDR, the Medical Device Directive (93/42/EEC) and other applicable regulations for the markets in which we sell.
Partnerships
- In 2025, we also acquired VirtuOx, an independent diagnostic testing facility, to expand our ability to partner with healthcare providers and to help streamline the diagnostic process, while expanding collaboration with home medical equipment providers to efficiently support patients to start treatment. •Accelerate Market Growth through Awareness.
- The current impact of global tariffs is dynamic, however, new or increased tariffs, reciprocal tariffs, or other disruptions to global trade could have a material impact on our business and financial results through interruption of supply chains, increases in our costs or reduction in the availability of key inputs as our suppliers deal with an uncertain global trade environment, increases in transportation costs, or disruption of global shipping.
Legal & Regulatory Risks (Item 1A, quoted)
- Our use and disclosure of personal information, including health information, is subject to federal, state and foreign privacy, artificial intelligence, data, biometrics and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability, regulatory investigations, legal actions, or reputational harm.
- Our business activities are subject to extensive regulation, and any failure to comply could have a material adverse effect on our business, financial condition, or results of operations.
- Our use of artificial intelligence in certain products, software solutions and business operations may expose us to operational, regulatory and reputational risks that could adversely affect our business, financial condition and results of operations.
- Product sales, introductions or modifications may be delayed or canceled as a result of FDA regulations or similar foreign regulations, which could cause our sales and profits to decline.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:46 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt